US2023113863A1PendingUtilityA1

Selective Antisense Compounds and Uses Thereof

Assignee: IONIS PHARMACEUTICALS INCPriority: Aug 11, 2011Filed: Apr 4, 2022Published: Apr 13, 2023
Est. expiryAug 11, 2031(~5 yrs left)· nominal 20-yr term from priority
C12N 2310/3341C12N 2310/315C12N 2320/34C12N 2310/3125C12N 15/113C12N 2310/351C12N 2310/3231C12N 2310/11C12N 15/111C12N 2310/341C12N 2310/312C12N 2310/316C12N 2310/321C12N 2310/314
83
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

Claims

exact text as granted — not AI-modified
1 . A oligomeric compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein the modified oligonucleotide has a modification motif comprising:
 a 5′-region consisting of 2-8 linked 5′-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 5′-region nucleoside is a modified nucleoside and wherein the 3′-most 5′-region nucleoside is a modified nucleoside;   a 3′-region consisting of 2-8 linked 3′-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3′-region nucleoside is a modified nucleoside and wherein the 5′-most 3′-region nucleoside is a modified nucleoside; and   a central region between the 5′-region and the 3′-region consisting of 6-12 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-most central region nucleoside is an unmodified deoxynucleoside and the 3′-most central region nucleoside is an unmodified deoxynucleoside;   wherein the modified oligonucleotide has a nucleobase sequence complementary to the nucleobase sequence of a target region of a nucleic acid associated with a huntingtin transcript.   
     
     
         2 .- 272 . (canceled)

Join the waitlist — get patent alerts

Track US2023113863A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.